Among the 10 Antiretrovirals with the Highest Part D Spending in 2017, All Had List Price Increases Exceeding Inflation
All 10 Part D ARVs w Highest Spending Had Price Increases Above Inflation Download
View the Latest: Medicare Part D
Filter
-
-
Among the Most Commonly Used Antiretrovirals Covered by Part D in 2017, 9 of 10 Had List Prices Exceeding Inflation
Feature9 of 10 Most Commonly Used ARVs in Part D Had List Prices Above Inflation Download
-
Explainer Video Breaks Down Prescription Drug Rebates and Why They Matter in the Debate About Prescription Drug Costs
News ReleaseA new KFF animation explains how rebates for prescription drugs work, including how they are determined, who benefits from them, how they affect spending by insurers and consumers and the role of pharmacy benefit managers in the process. The Trump Administration had proposed banning such rebates in Medicare Part D, but dropped the proposal amid concerns that it would lead to higher costs for insurers, consumers and the Medicare program. It is still possible that…
-
Data Note: Prescription Drugs and Older Adults
Issue BriefThis data note explores the attitudes and experiences of older adults, ages 65 and up, when it comes to prescription drugs and related policy proposals being discussed. Experiences across different demographic groups are explored, such as household income and health status.
-
A Current Snapshot of the Medicare Part D Prescription Drug Benefit
Issue BriefThis brief provides an overview of the Medicare Part D prescription drug benefit, including current data on plan availability, enrollment, and spending and financing, and highlights changes made under the Inflation Reduction Act.
-
The First-Ever Government Negotiation Process for Drugs Has Finished, But the Politics Are Ongoing
PerspectiveThis post for Health Affairs Forefront examines how the results of the first-ever Medicare drug price negotiations will generate savings for the government and for Medicare beneficiaries, and how candidates' views on the issue could play a role in the upcoming elections and in the future of government negotiation.
-
KFF Health Tracking Poll September 2024: Support for Reducing Prescription Drug Prices Remains High, Even As Awareness of IRA Provisions Lags
FeatureMore than two years ago President Biden signed into law Medicare drug pricing provisions in the Inflation Reduction Act. KFF's September Health Tracking Poll examines voter's views on these provisions and finds that large majorities of voters are unaware of the provisions despite reporting support for them.
-
Medicare Advantage Payments to Increase Again
Quick InsightsThe increase translates into an additional $35 billion to Medicare Advantage plans in 2026 compared to this year….The increase in payments is larger than for 2025 (3.7%) or 2024 (3.3%), but below the increase for 2023 (8.5%), and comes at a time of increasing scrutiny over Medicare Advantage payments.
-
Open Enrollment: Insights from Medicare for Health Insurance Marketplaces
PerspectiveThis Policy Insight draws on the experiences of Medicare beneficiaries during Medicare’s annual enrollment period to consider whether consumers with health insurance coverage through the Affordable Care Act’s new marketplaces will shop for a better deal during their open enrollment season.
-
Open Enrollment: Insights from Medicare for Health Insurance Marketplaces
News ReleaseIn the latest post in the Policy Insights series, Tricia Neuman draws on the experiences of Medicare beneficiaries during Medicare’s annual enrollment period to consider whether consumers with health insurance coverage through the Affordable Care Act’s new marketplaces will shop for a better deal during their open enrollment season. Previous columns in the Policy Insights series are also available on kff.org.